NCT03588078View on ClinicalTrials.gov

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 15, 2018

Primary Completion Date

May 1, 2020

Study Completion Date

May 15, 2021

Conditions
Myelodysplastic Syndrome With Gene MutationAcute Myeloid Leukemia With Gene MutationsMyeloproliferative NeoplasmChronic Myelomonocytic Leukemia
Interventions
DRUG

APR-246

Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose

DRUG

Azacitidine

azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2

Trial Locations (7)

31059

Odile Beyne Rosy, Toulouse

44093

Dr Pierre Peterlin and Pr Patrice Chevalier, Nantes

59037

Bruno Quesnel, Lille

75010

Hôpital Saint Louis - Hématologie Séniors, Paris

75679

Hôpital Cochin/Service d'Hématologie, Paris

76038

Aspasia Stamatoullas, Rouen

06200

Hôpital Archet 1, Nice

Sponsors

Collaborators (1)

Aprea Therapeutics
All Listed Sponsors
collaborator

Aprea Therapeutics

INDUSTRY

lead

Groupe Francophone des Myelodysplasies

OTHER